The Lupus Agencies of New York State (LANYS) recently announced another victory after Gov. Andrew Cuomo signed into the law the Lupus Education and Outreach Bill. The new legislation will bring essential lupus education to the public and to health professionals. The bill was passed unanimously in June by the…
Eye damage, also referred to as retinopathy, caused by systemic lupus erythematosus may be a sign of more severe disease, as patients with lupus retinopathy have kidney damage more often than patients without eye disease. As lupus retinopathy is suggested to reflect damage to small blood vessels throughout the body,…
Those who develop lupus as youngsters have more severe symptoms and a higher chance of an earlier death, according to a new study. The study in the British journal Lupus suggests that since patients with juvenile-onset systemic lupus erythematosus (JSLE) constitute a high-risk group, doctors need to devote extra attention…
The American Autoimmune Related Diseases Association (AARDA) recently announced its latest #AutoimmuneHeroes — its 22 Scientific Advisory Board (SAB) members who, over the past 25 years, have contributed their time and talents to advancing the association and helping it realize its goals of promoting research into lupus and other autoimmune…
A research study has shown the efficacy and safety of the Benlysta (belimumab), used in combination with other standard of care lupus treatments, such as antimalarials (AM), immunosuppressants (IS) and steroids. The findings may contribute to a better understanding of how Benlysta works as an add-on therapy for systemic lupus erythematosus (SLE). The…
The Lupus Research Alliance, newly formed from the merger of three different lupus groups, had its debut at the recent Inaugural Gala in New York, a fundraising event that collected over $2.5 million to support lupus research initiatives. The gala was co-hosted by Robert Wood Johnson IV, Lupus Research Alliance chairman and chief executive…
Aurinia Pharmaceuticals’ voclosporin showed considerable success in a clinical trial of lupus nephritis, according to recent data released by the company. Results found that the drug met the study’s primary goal of complete remission, and met all secondary goals of the ongoing, Phase 2b AURA-LV trial (NCT02141672). The data were…
An unprecedented $3 million was raised to support lupus research through two fundraising efforts, the 2016 Walk with Us to Cure Lupus program and the TCS NYC Marathon team, the Lupus Research Alliance announced. In total, the national Walk program has raised about $33.5 million since its 2002 inception, the Lupus Research Alliance said in a press…
Prolonged treatment with Benlysta (belimumab) offers safe and effective control of disease activity, improves life quality and eases fatigue in patients with active, autoantibody-positive systemic lupus erythematosus (SLE), according to seven-year clinical trial results released by GSK, the drug’s developer. These findings come from a continuation study of patients who completed the Phase…
Mallinckrodt Pharmaceuticals announced the enrollment of the first patients in the company’s Phase 4 clinical trial of H.P. Acthar Gel (repository corticotropin injection) for the treatment of systemic lupus erythematosus (SLE) patients with persistently active disease. The randomized and double-blind study (NCT02953821) will assess the effectiveness of the gel against…